JP2016500073A - 寄生虫病の処置のための化合物および組成物 - Google Patents

寄生虫病の処置のための化合物および組成物 Download PDF

Info

Publication number
JP2016500073A
JP2016500073A JP2015543098A JP2015543098A JP2016500073A JP 2016500073 A JP2016500073 A JP 2016500073A JP 2015543098 A JP2015543098 A JP 2015543098A JP 2015543098 A JP2015543098 A JP 2015543098A JP 2016500073 A JP2016500073 A JP 2016500073A
Authority
JP
Japan
Prior art keywords
pyrazine
carboxamide
methyl
imidazo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500073A5 (enExample
Inventor
クマール チャタージー，アーナブ
クマール チャタージー，アーナブ
スレシュ ネーグル，アドベイト
スレシュ ネーグル，アドベイト
パラセリ，プラスナ
ヨン レオン，セ
ヨン レオン，セ
トーマス ローランド，ジェイソン
トーマス ローランド，ジェイソン
クマール ミシュラ，プラナブ
クマール ミシュラ，プラナブ
ケーエス ユン，ブライアン
ケーエス ユン，ブライアン
ツォウ，ビン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016500073A publication Critical patent/JP2016500073A/ja
Publication of JP2016500073A5 publication Critical patent/JP2016500073A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015543098A 2012-11-19 2013-11-18 寄生虫病の処置のための化合物および組成物 Pending JP2016500073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728024P 2012-11-19 2012-11-19
US61/728,024 2012-11-19
PCT/US2013/070623 WO2014078813A1 (en) 2012-11-19 2013-11-18 Compounds and compositions for the treatment of parasitic diseases

Publications (2)

Publication Number Publication Date
JP2016500073A true JP2016500073A (ja) 2016-01-07
JP2016500073A5 JP2016500073A5 (enExample) 2016-12-28

Family

ID=49667633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543098A Pending JP2016500073A (ja) 2012-11-19 2013-11-18 寄生虫病の処置のための化合物および組成物

Country Status (5)

Country Link
US (1) US20150291598A1 (enExample)
EP (1) EP2920177A1 (enExample)
JP (1) JP2016500073A (enExample)
CN (1) CN105189506A (enExample)
WO (1) WO2014078813A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018199210A1 (ja) * 2017-04-27 2018-11-01 日本農薬株式会社 縮合複素環化合物又はその塩類、及びそれらの化合物を含有する農園芸用殺虫剤並びにその使用方法
JP2020506172A (ja) * 2017-01-16 2020-02-27 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 化合物及び住血吸虫症の治療におけるそれらの使用
KR20210032407A (ko) * 2018-07-17 2021-03-24 메르크 파텐트 게엠베하 간질병 치료에 사용하기 위한 화합물
JP2022553261A (ja) * 2019-10-21 2022-12-22 ノバルティス アーゲー 寄生虫病の処置のための化合物及び組成物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2920177A1 (en) * 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
HRP20171998T1 (hr) 2012-11-19 2018-02-09 Novartis Ag Spojevi i sastavi za liječenje parazitnih bolesti
KR102565544B1 (ko) * 2014-06-25 2023-08-10 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 이미다조[1,2-a]피라진-1일-벤즈아마이드 화합물
PE20171307A1 (es) 2014-12-23 2017-09-05 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
CN104610229B (zh) * 2015-01-21 2017-01-18 上海皓元生物医药科技有限公司 一种是atp竞争性小分子akt抑制剂a443654的合成方法
KR102519922B1 (ko) 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
US11584744B2 (en) * 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
KR20200022027A (ko) * 2017-06-30 2020-03-02 리부 세라퓨틱스 에스.에이. 아데노신 A2A 수용체의 이미다조[1,2,a]피라진 조절물질
WO2019051642A1 (zh) * 2017-09-12 2019-03-21 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
EP3746071A4 (en) 2018-01-29 2021-09-01 Merck Patent GmbH GCN2 INHIBITORS AND THEIR USES
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
US11952387B2 (en) 2018-08-21 2024-04-09 Kyorin Pharmaceutical Co., Ltd Bicyclic heteroaromatic ring derivative
TW202039512A (zh) 2018-12-06 2020-11-01 日商第一三共股份有限公司 環烷-1,3-二胺化合物
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
WO2024022910A1 (en) 2022-07-26 2024-02-01 Syngenta Crop Protection Ag 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides
WO2024213651A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
AR132352A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de imidazo[1,2-a]pirazina
AR132358A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados bicíclicos de imidazo
CN121002016A (zh) * 2023-04-13 2025-11-21 先正达农作物保护股份公司 咪唑并[1,2-a]吡啶衍生物
WO2024213650A1 (en) * 2023-04-13 2024-10-17 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
TW202446263A (zh) * 2023-04-13 2024-12-01 瑞士商先正達農作物保護股份公司 殺真菌組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516774A (ja) * 2007-01-26 2010-05-20 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリア原虫関連疾患を処置するためのキナーゼ阻害剤としてのプリン化合物および組成物
WO2011006143A2 (en) * 2009-07-09 2011-01-13 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2920177A1 (en) * 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516774A (ja) * 2007-01-26 2010-05-20 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリア原虫関連疾患を処置するためのキナーゼ阻害剤としてのプリン化合物および組成物
WO2011006143A2 (en) * 2009-07-09 2011-01-13 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506172A (ja) * 2017-01-16 2020-02-27 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 化合物及び住血吸虫症の治療におけるそれらの使用
JP7101683B2 (ja) 2017-01-16 2022-07-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 化合物及び住血吸虫症の治療におけるそれらの使用
WO2018199210A1 (ja) * 2017-04-27 2018-11-01 日本農薬株式会社 縮合複素環化合物又はその塩類、及びそれらの化合物を含有する農園芸用殺虫剤並びにその使用方法
JPWO2018199210A1 (ja) * 2017-04-27 2020-02-27 日本農薬株式会社 縮合複素環化合物又はその塩類、及びそれらの化合物を含有する農園芸用殺虫剤並びにその使用方法
US11064699B2 (en) 2017-04-27 2021-07-20 Nihon Nohyaku Co., Ltd. Condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide
KR20210032407A (ko) * 2018-07-17 2021-03-24 메르크 파텐트 게엠베하 간질병 치료에 사용하기 위한 화합물
JP2021530509A (ja) * 2018-07-17 2021-11-11 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングMerck Patent GmbH 肝蛭症の処置に使用される化合物
JP7449270B2 (ja) 2018-07-17 2024-03-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 肝蛭症の処置に使用される化合物
KR102819209B1 (ko) 2018-07-17 2025-06-10 메르크 파텐트 게엠베하 간질병 치료에 사용하기 위한 화합물
JP2022553261A (ja) * 2019-10-21 2022-12-22 ノバルティス アーゲー 寄生虫病の処置のための化合物及び組成物
JP7634532B2 (ja) 2019-10-21 2025-02-21 ノバルティス アーゲー 寄生虫病の処置のための化合物及び組成物

Also Published As

Publication number Publication date
WO2014078813A1 (en) 2014-05-22
US20150291598A1 (en) 2015-10-15
CN105189506A (zh) 2015-12-23
EP2920177A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
JP2016500073A (ja) 寄生虫病の処置のための化合物および組成物
JP6298472B2 (ja) 寄生虫病の処置のための化合物および組成物
TWI535442B (zh) A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
TWI743401B (zh) 吲哚甲醯胺化合物
CN103038229B (zh) 杂芳基化合物及其使用方法
TWI839363B (zh) 嘧啶化合物及包括其之供預防或治療癌症的藥學組成物
CA2845578C (en) Pyrimidine pde10 inhibitors
JP7451765B2 (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
TW201726623A (zh) 作為免疫調節劑之雜環化合物
US9233961B2 (en) Compounds and compositions for the treatment of parasitic diseases
JP6392352B2 (ja) リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
JP2017522340A (ja) ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用
KR20170075756A (ko) 카르바졸 유도체
CN103402520A (zh) 具有取代基的咪唑并喹啉衍生物
TW202509031A (zh) Ｃｄｋ抑制劑萘啶化合物
TW202339721A (zh) Bcl-xL抑制劑
TW201605858A (zh) 縮合吡唑衍生物
US8871754B2 (en) Compounds and compositions for the treatment of parasitic diseases
JP7710756B2 (ja) Ｃｔｌａ－４低分子分解剤及びその使用
JP2023545452A (ja) クリプトスポリジウム症の治療のための化合物及び組成物
HK1226725A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
HK1226725B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
HK1236925A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180320